Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study

Woldu, Solomon; Matulay, Justin; Clinton, Timothy; Singla, Nirmish; Freifeld, Yuval; Sanli, Mehmet; Krabbe, Laura-Maria; Hutchinson, Ryan; Lotan, Yair; Hammers, Hans; Hannan, Raquibul; Brugarolas, James; Bagrodia, Aditya; Margulis, Vitaly

doi:10.1016/j.clgc.2018.08.001

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study

Woldu S. L., Matulay J. T., Clinton T. N., Singla N., Freifeld Y., Sanli O., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.16, sa.6, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Sayı: 6
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.clgc.2018.08.001
Dergi Adı: CLINICAL GENITOURINARY CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Kidney cancer, Surveillance, Systemic therapy, Tyrosine kinase inhibitor, Watchful waiting, ACTIVE SURVEILLANCE, INTERFERON-ALPHA, EFFICACY, WATCH
İstanbul Üniversitesi Adresli: Evet

Özet

The National Cancer Data Base was analyzed to evaluate the impact of delaying initiation of targeted therapy (TT) for metastatic renal-cell carcinoma. After correction for various clinicopathologic factors, delayed initiation of TT was not associated with worse overall survival. This finding supports a practice that appears to be commonplace clinically, although is seldom reported in the literature.